Targeting the interaction between immunosuppressive cancer-associated fibroblasts and macrophages in the tolerogenic tumor microenvironment by CXCR4-A-armed oncolytic virotherapy transiently reverses CD8+ T cell tolerance to tumor/self-antigen and increases therapeutic efficacy in an immunocompetent ovarian cancer model. This evidence concerns the gene CXCR4 and ovarian cancer.